Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Galapagos Sells CRO To Selvita For €31.2m

Fidelta No Longer Fits Strategy

Executive Summary

The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.

You may also be interested in...



Galapagos Knocked By Knee Osteoarthritis Fail

Still reeling from the FDA rejection of its JAK inhibitor filgotinib for rheumatoid arthritis, the Belgium-headquartered biotech's ADAMTS-5 inhibitor developed with France's Servier is sunk after failing to significantly reduce cartilage loss compared with placebo in an OA trial.

Gilead’s RA Hopeful Filgotinib Hit By Complete Response Letter

Complete Response Letter is a major setback for Gilead and its partner Galapagos.

Poland’s Ryvu To Feed Galapagos’ R&D Effort

Ryvu Therapeutics has added to its drug discovery collaborators with an early-stage deal with Belgium’s Galapagos. 

 

 

Topics

Related Companies

UsernamePublicRestriction

Register

SC143371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel